Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors

Phase 1 Completed 18 enrolled Kyushu University Human Genome Center, Institute of Medical Science, University of Tokyo · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the clinical safety and efficacies of cyclophosphamide combined cancer specific epitope peptides cocktail for advanced/relapsed solid tumors including GI/lung/cervical cancers

Timeline

Start: 2007-11
Primary completion: 2010-03
Completion: 2010-03

Publications

Background Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. doi: 10.1158/0008-5472.CAN-04-3759.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1	Vaccine	1 mg	Subcutaneous

Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors

Summary

Timeline

Publications

Drugs

Indications